TEL AVIV, Israel, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2014 before the market open, and will host a corporate update conference call and webcast on Thursday, February 12 at 8:30am Eastern Time.
|
Conference Call & Webcast |
|
Thursday, February 12 @ 8:30am Eastern Time/5:30am Pacific Time |
|
Domestic: |
855-469-0611 |
|
International: |
484-756-4341 |
|
Passcode: |
74833931 |
|
Webcast: |
http://www.alcobra-pharma.com/indexInvestor.cfm |
|
|
|
|
Replays available through February 26, 2015 |
|
|
Domestic: |
855-859-2056 |
|
International: |
404-537-3406 |
|
Passcode: |
74833931 |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed multiple Phase II studies and a Phase III study in adults with ADHD. The company is conducting separate Phase II trials in pediatric ADHD and Fragile X Syndrome. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
CONTACT: U.S. Investor Contacts
LifeSci Advisors, LLC
Michael Rice
646-597-6979
mrice@lifesciadvisors.com
Media Inquiries
Sam Brown, Inc.
Mike Beyer
773-463-4211
mikebeyer@sambrown.com
Israel Investor Contact:
Alcobra Investor Relations
Debbie Kaye
+972-72 2204661
debbie@alcobra-pharma.com
